4.2 Review

Understanding and treating pulmonary hypertension in congenital diaphragmatic hernia

Journal

SEMINARS IN FETAL & NEONATAL MEDICINE
Volume 19, Issue 6, Pages 357-363

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.siny.2014.09.008

Keywords

Congenital diaphragmatic hernia; Lung hypoplasia; Pulmonary hypertension; Vasodilator therapy; Prenatal therapy

Categories

Funding

  1. Canadian Institute of Health Research
  2. Heart and Stroke Foundation Canada
  3. Ontario Thoracic Society
  4. Children's Hospital of Eastern Ontario Research Institute
  5. Ottawa Hospital Research Institute

Ask authors/readers for more resources

Lung hypoplasia and pulmonary hypertension are classical features of congenital diaphragmatic hernia (CDH) and represent the main determinants of survival. The mechanisms leading to pulmonary hypertension in this malformation are still poorly understood, but may combine altered vasoreactivity, pulmonary artery remodeling, and a hypoplastic pulmonary vascular bed. Efforts have been directed at correcting the reversible component of pulmonary hypertension of CDH. However, pulmonary hypertension in CDH is often refractory to pulmonary vasodilators. A new emerging pattern of late (months after birth) and chronic (months to years after birth) pulmonary hypertension are described in CDH survivors. The true incidence and implications for outcome and management need to be confirmed by follow-up studies from referral centers with high patient output. In order to develop more efficient strategies to treat pulmonary hypertension and improve survival in most severe cases, the ultimate therapeutic goal would be to promote lung and vascular growth. (C) 2014 Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available